Menopause and Tinnitus: What the Research Says About What to Do

Yes — tinnitus during perimenopause is common, and for most women it is not permanent. Research suggests a meaningful connection between hormonal fluctuation and auditory system stability, and clinical guidelines have clear recommendations for the first steps. Here is what the published evidence shows, and what is worth discussing with your doctor.

Tinnitus during menopause is common — research suggests new or worsening tinnitus is reported by a substantial proportion of women during perimenopause. In most cases it is not permanent, but the right workup depends on timing, pattern, and whether hearing loss is present. Three things that audiologists and ENT clinicians typically recommend as first steps: a full hearing evaluation, tracking whether your symptoms fluctuate with your cycle or symptoms, and letting your gynaecologist know about the timing. Whether any of these apply to your situation is a conversation to have with your doctor.

Is menopause tinnitus different from other tinnitus?

Research suggests there may be a meaningful hormonal component for some women.

Most tinnitus develops following noise-related cochlear damage. Tinnitus that begins in perimenopause — the 2–10 year window before periods stop — sometimes arises in women with no significant noise history. A 2006 review in Acta Oto-Laryngologica noted that oestrogen receptors are present throughout the auditory system, including the cochlea, and that oestrogen fluctuation may affect auditory processing stability.¹ The same review found mixed evidence on hormone replacement therapy: some studies showed slight hearing benefit, while others showed no consistent effect.

What this means in practice: if your tinnitus began in your mid-40s to early 50s, varies week to week, and you have no significant noise exposure history, the menopause timing is relevant information to bring to your audiologist and gynaecologist. It does not confirm a hormonal cause, and it does not change the first clinical step — which is a hearing evaluation.

One widely-cited model in tinnitus research is the central gain model. When the cochlea's output to the auditory brainstem is reduced — due to hair cell decline from ageing, noise exposure, or other causes — the central auditory system compensates by increasing its own neural amplification. This homeostatic response can inadvertently amplify internal neural noise, generating tinnitus. Schaette & McAlpine (2011) demonstrated this mechanism in people with normal audiograms but underlying cochlear damage, a condition termed "hidden hearing loss."^S1 How hormonal changes during menopause interact with cochlear hair cell function and central gain is still being studied — the connection is biologically plausible but not yet directly established in controlled research. Presenting this timing to both your gynaecologist and your audiologist gives them the most complete picture.

Should I get a hearing test?

Audiology guidelines consistently recommend a hearing evaluation as the first step in assessing new-onset tinnitus.²

The reason: tinnitus and hearing loss are separate conditions that frequently occur together. Significant high-frequency hearing loss can be present without noticeable difficulty in everyday conversation.

The audiogram is diagnostic, not therapeutic — it tells you and your clinician what is actually happening in the inner ear, which determines what options are appropriate. Whether a hearing aid is relevant, whether further investigation is needed, and which types of sound-based support are suitable all depend on what the audiogram shows.

What does the research say about hormone replacement therapy and tinnitus?

The published evidence is genuinely uncertain, and clinicians are appropriately cautious.

The Hultcrantz review (2006) found that menopausal women receiving HRT showed slightly better hearing on some measures compared to untreated groups — but also noted that combination HRT (oestrogen plus progestogen) may in some cases have negative effects on auditory function.¹ The review described these contradictory findings as reflecting the complex, receptor-specific actions of oestrogen.

What this means for you: the evidence is not strong enough to start or stop HRT based on tinnitus alone. If you are considering HRT for other menopause symptoms, or are already on it, the right conversation is with the clinician managing your menopause care — not a decision to make based on this article. Bring up the tinnitus timing; they may find it clinically relevant.

What does research say helps with tinnitus related to menopause or hormonal changes?

Audiologists and tinnitus specialists typically refer to a range of options, with different levels of evidence. Here is what the published literature says — whether any of these are appropriate for your specific situation is a clinical decision.

If hearing loss is present:
Published guidelines support hearing aids for tinnitus management in people with confirmed hearing loss — amplification of ambient sound reduces the relative contrast of the tinnitus signal.² This applies only when hearing loss is confirmed on audiometry.

Sound enrichment in quiet environments:
A 2012 Cochrane systematic review examined sound-based therapies for tinnitus across multiple trials (Hobson et al., 2012).³ The review found the available evidence was limited and did not demonstrate significant changes in tinnitus loudness or severity. The authors noted this absence of strong evidence should not be taken as proof of ineffectiveness, and that sound enrichment is widely used in clinical practice as part of broader management programmes.

CBT-based tinnitus therapy:
A randomised controlled trial published in The Lancet (Cima et al., 2012) compared specialised CBT-based treatment for tinnitus against usual care and found significantly greater reduction in tinnitus-related disability in the CBT group, with effects maintained at 12 months.⁴ The Cima trial did not specifically study menopause-related tinnitus — it enrolled a broad tinnitus population. Your clinician can advise whether CBT-based approaches are appropriate for your presentation.

Is whether any of these options is suitable for your situation a conversation to have with your audiologist or clinician.

Is there a severity measure I should know about?

The Tinnitus Functional Index (TFI) is a validated 25-item questionnaire used in clinical research and practice to measure tinnitus impact across dimensions including sleep, concentration, and emotional distress. It takes approximately 5 minutes. Published research uses it as a primary outcome measure in multiple clinical trials, including the Cima 2012 Lancet study.

If you take a baseline measurement before starting any intervention, you and your clinician have a reference point for evaluating whether anything is working. A free TFI assessment is available at silenear.com/tfi-assessment/

When does menopause tinnitus resolve on its own?

There is no reliable clinical predictor for individual outcomes. Some women report improvement after hormonal transition stabilises post-menopause; others find it persists. What the tinnitus research literature consistently shows is that the pattern of distress — how intrusive the tinnitus is — can improve substantially with appropriate support even when the tinnitus sound itself persists (Cima et al., 2012).⁴

What are the current treatment options?

Listed for information. Suitability depends on your specific hearing profile, tinnitus pattern, and clinical history — your audiologist and ENT are best placed to advise.

Evidence-based approaches used in clinical practice:

• CBT for tinnitus — strongest published evidence for reducing tinnitus distress (Cima et al., 2012)⁴
• Hearing aids — supported when hearing loss is confirmed (Tunkel et al., 2014)²
• Sound enrichment — commonly used as part of broader management, limited standalone evidence (Hobson et al., 2012)³
• TRT (Tinnitus Retraining Therapy) — directive counselling combined with sound enrichment; evidence base reviewed

Medical devices:
Lenire — bimodal neuromodulation device (sound + tongue stimulation), CE-marked and FDA-cleared. Published TENT-A1 trial (Conlon et al., 2020, Science Translational Medicine) showed statistically significant symptom reduction in 326 patients at 12 weeks, maintained at 12 months.⁵ Requires prescription through a licensed audiologist.

Commonly used without strong RCT evidence:
Supplements (ginkgo, zinc, magnesium) — widely used; no consistent evidence of benefit in randomised trials. Not known to be harmful.

Whether any of the above options is appropriate for your situation is a decision for your clinician. Bringing this article's reference list to your appointment may help focus the conversation.

← Back to all posts